Tag: PA

Poster-Disease-modifying Therapy

Therapy Selection Considerations during the COVID-19 Pandemic Among Patients with Progressive Multiple Sclerosis: Analyses from Retrospective Patient Chart Audit

Background: In March 2020, the onset of the COVID-19 pandemic in the United States introduced new concerns related to the treatment of...

Read More

Poster-Disease-modifying Therapy

Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening – Early 3 Months Post Approval Data

Background: Superior efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. Objectives: The social media...

Read More

Poster-Disease-modifying Therapy

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study

Background: Siponimod is a selective S1P receptor (S1P1 and S1P5) modulator, approved in the USA for treatment of relapsing forms of MS,...

Read More

Poster-Disease-modifying Therapy

Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19

Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...

Read More

Poster-Disease-modifying Therapy

Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data

Background: The efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. This analysis provides the first account...

Read More

Poster-Disease-modifying Therapy

Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies

Background: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by many factors that are not...

Read More

Poster-Disease-modifying Therapy

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...

Read More

Poster-Case Reports / Case Series

Delayed Visual Improvement in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis

Background: Bilateral involvement and severe visual impairment can occur in the acute phase of pediatric myelin oligodendrocyte...

Read More

Platform-Disease Modifying Therapies

Design of the Phase II, Double-Blind, Placebo-Controlled Dose-Expansion Portion of a Two-Part, Phase I/II, Multicenter Trial in Progressive Multiple Sclerosis

Background: Infection with Epstein-Barr virus (EBV) is a necessary risk factor for the development of multiple sclerosis (MS) Abrahamyan S...

Read More

Platform-Neuroimaging

International Magnims-CMSC-Naims Consensus Recommendations on the Use of Standardized MRI in MS

Background: Standardized magnetic resonance imaging (MRI) guidelines published in 2015 by the MAGNIMS group and in 2016 by the CMSC are...

Read More